MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
7.88
-0.59
-6.97%
After Hours: 7.81 -0.07 -0.89% 16:31 03/04 EST
OPEN
8.50
PREV CLOSE
8.47
HIGH
8.50
LOW
7.72
VOLUME
263.15K
TURNOVER
0
52 WEEK HIGH
10.46
52 WEEK LOW
4.000
MARKET CAP
218.78M
P/E (TTM)
-4.1110
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATNM last week (0226-0301)?
Weekly Report · 15h ago
Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)
Seeking Alpha · 5d ago
Buy Rating Justified by Actinium Pharmaceuticals’ Iomab-B Clinical and Commercial Promise
TipRanks · 6d ago
Iomab-B’s Breakthrough Potential in AML Treatment Bolsters Buy Rating for Actinium Pharmaceuticals
TipRanks · 6d ago
Actinium shares surge on promising data for AML radiotherapy candidate
Seeking Alpha · 6d ago
Actinium: Iomab-B Increases Long Term Survival In 65 Years Or Older AML Patients In Phase 3 Trial
NASDAQ · 02/26 13:38
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Actinium Pharmaceuticals, Inc. Reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B. Active relapsed or refractory AML patients 65+ years receiving an IomAB-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients. Unprecedented 100% access to potentially curative bone marrow transplant in patients with high-risk features including a TP53 mutation. Iom ab-B improved long-term survival outcomes greater than 2 years in patients age 65 or older.
PR Newswire · 02/26 12:30
Weekly Report: what happened at ATNM last week (0219-0223)?
Weekly Report · 02/26 09:56
More
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The Company develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.